Want to take quizzes and track your credits?
Studies have reported low seroconversion rates (58% after the second dose) in solid organ transplant recipients who received a messenger RNA (mRNA) SARS-CoV-2 vaccine.1,2 Based on this evidence, the French National Authority for Health issued a recommendation in April 2021 to administer a third vaccine dose in immunosuppressed patients who did not respond after 2 doses. We examined the antibody responses of kidney transplant recipients who did not respond to 2 doses and received a third dose (100 μg) of the mRNA-1273 (Moderna) vaccine.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Corresponding Author: Sophie Caillard, MD, PhD, Department of Nephrology and Transplantation, Strasbourg University Hospital, 1 Place de l’hôpital, 67091 Strasbourg, France (firstname.lastname@example.org).
Accepted for Publication: July 9, 2021.
Published Online: July 23, 2021. doi:10.1001/jama.2021.12339
Author Contributions: Drs Benotmane and Caillard had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Benotmane, Caillard.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Benotmane, Caillard.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Benotmane, Caillard.
Administrative, technical, or material support: Gautier Vargas, Olagne, Cognard, Fafi-Kremer, Caillard.
Conflict of Interest Disclosures: Dr Caillard reported receiving travel grants from Astellas, Novartis, and Sanofi and receiving lecture honoraria from Bristol Myers Squibb. Dr Benotmane reported receiving travel grants from Novartis, Sandoz, Fresenius Medical Care, and Chiesi. No other disclosures were reported.
Additional Contributions: We thank all of the physicians (Jonas Martzloff, MD, Laura Braun Parvez, MD, Francoise Heibel, MD, Bruno Moulin, MD, PhD), the clinical research team (Danielle Roy, Annie Menguy, Hugo Servais), nurses (Sandra Ludwiller, Muriel Morvan, Karima Kedjam, Lucile Steinmetz, Christelle Appenzeller), and the secretaries (Amandine Bigot and Agathe Pillon) who work in the Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France, and who were involved in the vaccination program and patient follow-up. We are grateful to Marie Josée Wendling and Aurélie Velay (Department of Virology, Strasbourg University Hospital, Strasbourg, France) for their technical support and to Marc Hazzan (Department of Nephrology and Transplantation, Lille University Hospital, Lille, France) for statistical assistance. None of these individuals received compensation for their roles in the study.
You currently have no searches saved.